Stellar Biotechnologies Announces Collaboration with Amaran Biotechnology, Inc
Dec 12 13
Stellar Biotechnologies, Inc. announced that it has entered into a collaboration agreement with Amaran Biotechnology, Inc. to develop and evaluate methods for the manufacture of OBI-822 active immunotherapy using Stellar's GMP grade Keyhole Limpet Hemocyanin. Amaran designs, develops, and manufactures active immunotherapies such as OBI-822, the lead immunotherapy product of OBI Pharma, Inc. The primary purpose of the alliance is to develop and evaluate methods for the manufacture of the OBI-822 active immunotherapy using Stellar's GMP grade KLH. OBI-822 is a new generation of active immunotherapy combining Globo-H, a carbohydrate antigen frequently expressed by cancer cells, together with KLH as the immune-stimulating carrier molecule. An active immunotherapy uses a patient's own immune system to recognize and mount an attack against the targeted tumor cells. OBI-822 is currently being evaluated for the treatment of metastatic breast cancer in International Phase 2/3 clinical trials in the United States, Taiwan, South Korea, India and Hong Kong. It is also being evaluated for the treatment of ovarian cancer in an investigator-initiated Phase 1/2 clinical trial in Taiwan. Under the terms of the agreement, Stellar will be responsible for the production and delivery of GMP grade KLH for evaluation as a carrier molecule in OBI-822 immunotherapy. Stellar will also be responsible for method development, product formulation, and process qualification for certain KLH reference standards. Amaran will be responsible for development objectives and product specifications. The agreement provides for Amaran to pay to Stellar fees for certain expenses and costs associated with the development program. Subject to certain conditions and timing, the collaboration also provides for the companies to negotiate a commercial supply agreement for Stellar KLH(TM) in the future.
Amaran Biotechnology Inc. to Invest USD 33.41 Million in Taiwanese Factory for Botox Biosimilar
Jul 31 13
Amaran Biotechnology Inc. has announced plans to invest TWD 1 billion in a factory and research centre in Taiwan's Hsinchu Biomedical Science Park, Taipei, in relation to conducting clinical trials and manufacturing drugs developed by OBI Pharma Inc, a subsidiary of Optimer Pharmaceuticals. The new factory will initially focus on production of a biosimilar of botulinum toxin type A, otherwise known as Botox, for use in cosmetic surgery, along with other generic protein drugs, Amaran states. Amaran stated that the factory will have the capacity to produce OBI's flagship R&D hope, OBI-822, a first-in-class immunotherapy for metastatic breast cancer currently at the Phase II/III stage.